2024-02-052025-01-312025-01-31false10575824PRIVATE PHARMA LTD2025-10-30falseiso4217:GBPxbrli:pure105758242024-02-04105758242025-01-31105758242024-02-052025-01-31105758242023-01-25105758242024-02-04105758242023-01-262024-02-0410575824bus:SmallEntities2024-02-052025-01-3110575824bus:AuditExempt-NoAccountantsReport2024-02-052025-01-3110575824bus:FullAccounts2024-02-052025-01-3110575824bus:PrivateLimitedCompanyLtd2024-02-052025-01-3110575824core:WithinOneYear2025-01-3110575824core:AfterOneYear2025-01-3110575824core:WithinOneYear2024-02-0410575824core:AfterOneYear2024-02-0410575824core:ShareCapital2025-01-3110575824core:SharePremium2025-01-3110575824core:RevaluationReserve2025-01-3110575824core:OtherReservesSubtotal2025-01-3110575824core:RetainedEarningsAccumulatedLosses2025-01-3110575824core:ShareCapital2024-02-0410575824core:SharePremium2024-02-0410575824core:RevaluationReserve2024-02-0410575824core:OtherReservesSubtotal2024-02-0410575824core:RetainedEarningsAccumulatedLosses2024-02-0410575824core:LandBuildings2025-01-3110575824core:PlantMachinery2025-01-3110575824core:Vehicles2025-01-3110575824core:FurnitureFittings2025-01-3110575824core:OfficeEquipment2025-01-3110575824core:NetGoodwill2025-01-3110575824core:IntangibleAssetsOtherThanGoodwill2025-01-3110575824core:ListedExchangeTraded2025-01-3110575824core:UnlistedNon-exchangeTraded2025-01-3110575824core:LandBuildings2024-02-0410575824core:PlantMachinery2024-02-0410575824core:Vehicles2024-02-0410575824core:FurnitureFittings2024-02-0410575824core:OfficeEquipment2024-02-0410575824core:NetGoodwill2024-02-0410575824core:IntangibleAssetsOtherThanGoodwill2024-02-0410575824core:ListedExchangeTraded2024-02-0410575824core:UnlistedNon-exchangeTraded2024-02-0410575824core:LandBuildings2024-02-052025-01-3110575824core:PlantMachinery2024-02-052025-01-3110575824core:Vehicles2024-02-052025-01-3110575824core:FurnitureFittings2024-02-052025-01-3110575824core:OfficeEquipment2024-02-052025-01-3110575824core:NetGoodwill2024-02-052025-01-3110575824core:IntangibleAssetsOtherThanGoodwill2024-02-052025-01-3110575824core:ListedExchangeTraded2024-02-052025-01-3110575824core:UnlistedNon-exchangeTraded2024-02-052025-01-3110575824core:MoreThanFiveYears2024-02-052025-01-3110575824core:Non-currentFinancialInstruments2025-01-3110575824core:Non-currentFinancialInstruments2024-02-0410575824dpl:CostSales2024-02-052025-01-3110575824dpl:DistributionCosts2024-02-052025-01-3110575824core:LandBuildings2024-02-052025-01-3110575824core:PlantMachinery2024-02-052025-01-3110575824core:Vehicles2024-02-052025-01-3110575824core:FurnitureFittings2024-02-052025-01-3110575824core:OfficeEquipment2024-02-052025-01-3110575824dpl:AdministrativeExpenses2024-02-052025-01-3110575824core:NetGoodwill2024-02-052025-01-3110575824core:IntangibleAssetsOtherThanGoodwill2024-02-052025-01-3110575824dpl:GroupUndertakings2024-02-052025-01-3110575824dpl:ParticipatingInterests2024-02-052025-01-3110575824dpl:GroupUndertakingscore:ListedExchangeTraded2024-02-052025-01-3110575824core:ListedExchangeTraded2024-02-052025-01-3110575824dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-02-052025-01-3110575824core:UnlistedNon-exchangeTraded2024-02-052025-01-3110575824dpl:CostSales2023-01-262024-02-0410575824dpl:DistributionCosts2023-01-262024-02-0410575824core:LandBuildings2023-01-262024-02-0410575824core:PlantMachinery2023-01-262024-02-0410575824core:Vehicles2023-01-262024-02-0410575824core:FurnitureFittings2023-01-262024-02-0410575824core:OfficeEquipment2023-01-262024-02-0410575824dpl:AdministrativeExpenses2023-01-262024-02-0410575824core:NetGoodwill2023-01-262024-02-0410575824core:IntangibleAssetsOtherThanGoodwill2023-01-262024-02-0410575824dpl:GroupUndertakings2023-01-262024-02-0410575824dpl:ParticipatingInterests2023-01-262024-02-0410575824dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-262024-02-0410575824core:ListedExchangeTraded2023-01-262024-02-0410575824dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-262024-02-0410575824core:UnlistedNon-exchangeTraded2023-01-262024-02-0410575824core:NetGoodwill2025-01-3110575824core:IntangibleAssetsOtherThanGoodwill2025-01-3110575824core:LandBuildings2025-01-3110575824core:PlantMachinery2025-01-3110575824core:Vehicles2025-01-3110575824core:FurnitureFittings2025-01-3110575824core:OfficeEquipment2025-01-3110575824core:AfterOneYear2025-01-3110575824core:WithinOneYear2025-01-3110575824core:ListedExchangeTraded2025-01-3110575824core:UnlistedNon-exchangeTraded2025-01-3110575824core:ShareCapital2025-01-3110575824core:SharePremium2025-01-3110575824core:RevaluationReserve2025-01-3110575824core:OtherReservesSubtotal2025-01-3110575824core:RetainedEarningsAccumulatedLosses2025-01-3110575824core:NetGoodwill2024-02-0410575824core:IntangibleAssetsOtherThanGoodwill2024-02-0410575824core:LandBuildings2024-02-0410575824core:PlantMachinery2024-02-0410575824core:Vehicles2024-02-0410575824core:FurnitureFittings2024-02-0410575824core:OfficeEquipment2024-02-0410575824core:AfterOneYear2024-02-0410575824core:WithinOneYear2024-02-0410575824core:ListedExchangeTraded2024-02-0410575824core:UnlistedNon-exchangeTraded2024-02-0410575824core:ShareCapital2024-02-0410575824core:SharePremium2024-02-0410575824core:RevaluationReserve2024-02-0410575824core:OtherReservesSubtotal2024-02-0410575824core:RetainedEarningsAccumulatedLosses2024-02-0410575824core:NetGoodwill2023-01-2510575824core:IntangibleAssetsOtherThanGoodwill2023-01-2510575824core:LandBuildings2023-01-2510575824core:PlantMachinery2023-01-2510575824core:Vehicles2023-01-2510575824core:FurnitureFittings2023-01-2510575824core:OfficeEquipment2023-01-2510575824core:AfterOneYear2023-01-2510575824core:WithinOneYear2023-01-2510575824core:ListedExchangeTraded2023-01-2510575824core:UnlistedNon-exchangeTraded2023-01-2510575824core:ShareCapital2023-01-2510575824core:SharePremium2023-01-2510575824core:RevaluationReserve2023-01-2510575824core:OtherReservesSubtotal2023-01-2510575824core:RetainedEarningsAccumulatedLosses2023-01-2510575824core:AfterOneYear2024-02-052025-01-3110575824core:WithinOneYear2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:CostValuation2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-052025-01-3110575824core:Non-currentFinancialInstrumentscore:CostValuation2025-01-3110575824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-01-3110575824core:Non-currentFinancialInstrumentscore:CostValuation2024-02-0410575824core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-0410575824core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-0410575824bus:Director12024-02-052025-01-31

PRIVATE PHARMA LTD

Registered Number
10575824
(England and Wales)

Unaudited Financial Statements for the Period ended
31 January 2025

PRIVATE PHARMA LTD
Company Information
for the period from 5 February 2024 to 31 January 2025

Director

FEIKEN, Kirstina

Registered Address

Summit House 10 Waterside Court
Albany Street
Newport
NP20 5NT

Registered Number

10575824 (England and Wales)
PRIVATE PHARMA LTD
Statement of Financial Position
31 January 2025

Notes

31 Jan 2025

04 Feb 2024

£

£

£

£

Fixed assets
Tangible assets39792,859
9792,859
Current assets
Stocks164,000196,000
Debtors41,2412,576
Cash at bank and on hand4,49713,176
169,738211,752
Creditors amounts falling due within one year5(261,084)(307,176)
Net current assets (liabilities)(91,346)(95,424)
Total assets less current liabilities(90,367)(92,565)
Creditors amounts falling due after one year6(9,366)(15,050)
Net assets(99,733)(107,615)
Capital and reserves
Called up share capital100100
Profit and loss account(99,833)(107,715)
Shareholders' funds(99,733)(107,615)
The financial statements were approved and authorised for issue by the Director on 30 October 2025, and are signed on its behalf by:
FEIKEN, Kirstina
Director
Registered Company No. 10575824
PRIVATE PHARMA LTD
Notes to the Financial Statements
for the period ended 31 January 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going concern
After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Defined contribution pension plan
The company operates a defined contribution pension plan for the benefit of its employees. Contributions are recognised as expenses as they become payable. Differences between contributions payable in the year and those actually paid are recognised as either prepayments or accruals in the balance sheet. The assets of the defined contribution pension scheme are held separately from those of the company in an independently administered fund.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Straight line (years)
Office Equipment5
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
2.Average number of employees

20252024
Average number of employees during the year22
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 05 February 2432,03332,033
At 31 January 2532,03332,033
Depreciation and impairment
At 05 February 2429,17429,174
Charge for year1,8801,880
At 31 January 2531,05431,054
Net book value
At 31 January 25979979
At 04 February 242,8592,859
4.Debtors: amounts due within one year

2025

2024

££
Other debtors1,2412,576
Total1,2412,576
5.Creditors: amounts due within one year

2025

2024

££
Trade creditors / trade payables81,50846,826
Bank borrowings and overdrafts9,9009,900
Taxation and social security1,15060,703
Other creditors165,613188,333
Accrued liabilities and deferred income2,9131,414
Total261,084307,176
6.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts9,36615,050
Total9,36615,050
7.Controlling party
Ultimate control of the company is held by K Feiken.